Cardlytics (NASDAQ:CDLX) Receives “Hold” Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Cardlytics (NASDAQ:CDLX) in a research note issued to investors on Friday,Benzinga reports.

Several other analysts also recently commented on the stock. Craig Hallum raised shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th. Evercore ISI assumed coverage on shares of Cardlytics in a report on Friday, October 11th. They issued an “in-line” rating and a $4.00 price target on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $6.92.

Cardlytics Trading Up 3.3 %

NASDAQ CDLX opened at $3.16 on Friday. Cardlytics has a 12-month low of $2.76 and a 12-month high of $20.52. The company has a fifty day simple moving average of $3.69 and a two-hundred day simple moving average of $4.55. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. The stock has a market cap of $160.59 million, a P/E ratio of -0.52 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The company had revenue of $67.06 million during the quarter, compared to analyst estimates of $57.77 million. During the same quarter last year, the business posted ($0.26) EPS. The firm’s quarterly revenue was down 15.1% on a year-over-year basis. On average, analysts forecast that Cardlytics will post -1.52 earnings per share for the current year.

Insider Activity at Cardlytics

In other Cardlytics news, CFO Alexis Desieno sold 8,854 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $3.67, for a total value of $32,494.18. Following the sale, the chief financial officer now directly owns 121,976 shares of the company’s stock, valued at approximately $447,651.92. This trade represents a 6.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Amit Gupta sold 22,607 shares of the business’s stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the completion of the sale, the chief executive officer now owns 178,519 shares of the company’s stock, valued at $687,298.15. This trade represents a 11.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 69,007 shares of company stock worth $251,297 in the last three months. Company insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Cardlytics

A number of institutional investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP raised its position in Cardlytics by 1,273.2% during the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock worth $1,223,000 after acquiring an additional 354,474 shares during the period. Renaissance Technologies LLC raised its position in shares of Cardlytics by 711.9% during the 2nd quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after purchasing an additional 307,800 shares during the last quarter. RBF Capital LLC raised its position in shares of Cardlytics by 311.9% during the 3rd quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock worth $1,562,000 after purchasing an additional 369,620 shares during the last quarter. Geode Capital Management LLC lifted its stake in Cardlytics by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock valued at $3,371,000 after buying an additional 73,484 shares in the last quarter. Finally, Barclays PLC boosted its holdings in Cardlytics by 223.9% in the 3rd quarter. Barclays PLC now owns 58,026 shares of the company’s stock worth $186,000 after buying an additional 40,112 shares during the last quarter. Institutional investors and hedge funds own 68.10% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.